Singaporean authorities do not believe there is sufficient evidence supporting the efficacy of “raw” cannabis, considering the plant and its derivatives to be a dangerous drug with few medical benefits ...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
